Name: Chiara Raggi

Country: Italy


Humanitas Clinical and Research Center

Email: Send an Email


Liver Unit & Center for Autoimmune Liver Diseases,
Humanitas Clinical and Research Center Via Manzoni 113,
20089 Rozzano (MI)-Italy.

Research Interests:

Critical interaction between stem like compartment and inflammatory component in cholangiocarcinoma


  • Since 2007, Dr. Chiara Raggi has acquired a considerable professional experience in experimental oncology studying cellular and molecular aspects of human hepatocellularcarcinoma, in particular, focusing on CSC aspects of HCC. 
  • Dr. Raggi holds a PhD in General Pathology (University of Pisa). 
  • At the end of her PhD program, she joined as a post-doctoral fellow the Laboratory of Experimental Carcinogenesis at the National Cancer Institute (NCI/NIH) directed by Dr. Thorgeirsson SS to continue her studies on human carcinogenesis. 
  • At the LEC, Dr Raggi’s research work has been focused on the cellular and molecular aspects of human HCC. 
  • In particular, Dr Raggi has concentrated her activity on CSCs aspects of HCC in addition to participating to other projects at LEC. 
  • Within her research studies on the CSCs aspects of HCC, Dr Raggi has examined the role of epigenetic modifications on hepatic CSCs. 
  • One of her recent study (Hepatology,54(3):1031-42, 2011) demonstrated that epigenetic modulation may provide a tool for prospective isolation and in-depth analysis of CSCs.
  • Additionally, Dr Raggi has recently developed an innovative in vitro model to analyze CSC response to both cell microenvironment and epigenetic machinery. 
  • She has been able to demonstrate the importance of the interaction between epigenetic control and local microenvironment in defining the regulation of cancer stem/progenitor cells. 
  • Cellular context is a critical determinant in the response to DNMT1 inhibition resulting in either a long term epigenetically driven malignant reprogramming or an effective antitumor therapeutic reprogramming. 
  • These results identify DNA methylation as a key epigenetic regulatory mechanism determining the pool of cancer stem cells in liver cancer and possibly other solid tumors. 
  • This work has been submitted for publication in Hepatology journal.